|
시장보고서
상품코드
2074459
신속 미생물 검사 시장 : 제품별, 방법별, 용도별, 최종사용자별, 지역별 - 예측(-2031년)Rapid Microbiology Testing Market by Product (Instruments (Mass Spectrometers), Consumables), Method (Nucleic Acid-based), Application (Industrial Testing (Food & Beverage), Clinical Diagnosis), End User (Hospitals), & Region - Global Forecast to 2031 |
||||||
신속 미생물 검사 시장 규모는 2026년 56억 9,000만 달러에서 2031년까지 90억 달러로 성장하고, CAGR은 9.6%를 기록할 것으로 예측됩니다.
이 시장의 성장은 의약품 및 바이오의약품 생산 증가, 엄격한 무균성 및 오염 관리 요건, 그리고 분자진단 및 자동화 미생물 검사 시스템의 활용 확대에 힘입어 이루어지고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 산정 단위 | 금액(10억 달러) |
| 부문 | 제품별, 방법별, 용도별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
또한, 중합효소 연쇄반응(PCR), 질량 분석법 및 신속한 미생물 동정 기술의 발전으로 인해 검사실의 효율이 향상되었으며, 전 세계적으로 그 보급이 촉진되고 있습니다.
“제품별로는 시약 및 키트 부문이 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 보일 것으로 전망됩니다.”
시약 및 키트 부문의 성장은 주로 신속한 미생물학 워크플로우에 사용되는 배지, 분석 키트, 프라이머, 프로브, 염색제, 완충액 및 항균제 감수성 시험용 시약에 대한 지속적인 수요에 힘입어 이루어지고 있습니다. 감염병 발생률 증가와 무균성 확보 및 오염 관리에 대한 중요성이 부각됨에 따라, 병원, 제약·바이오기술 기업 및 식품 검사 기관에서의 검사 건수가 급증하고 있습니다. 또한, 분자미생물학 기술, 자동 검사 플랫폼 및 PCR 기반 신속 검사법의 도입 확대에 따라, 예측 기간 동안 시약 및 키트에 대한 수요가 더욱 증가할 것으로 예측됩니다.
“검사 방법별로는 2026년에 배양법에 기반한 부문이 신속 미생물 검사 시장에서 가장 큰 점유율을 차지할 것으로 전망됩니다.”
증식 기반의 신속 미생물 검사법은 제약 무균성 시험, 환경 모니터링, 식품 안전 검사 및 임상 미생물학 분야의 업무 흐름에서 널리 활용되고 있어, 2026년에는 시장을 독점할 것으로 전망됩니다. 증식 기반의 신속 미생물 검사법은 생존 가능한 미생물을 확실하게 검출할 수 있을 뿐만 아니라, 규제 준수 및 품질 보증 요건도 충족할 수 있어 널리 채택되고 있습니다. 자동 미생물 검출 시스템의 도입 확대, 오염의 신속한 파악에 대한 수요 증가, 그리고 의약품 및 바이오의약품 제조 활동의 확대가 이 부문의 성장을 더욱 뒷받침하고 있습니다. 또한, 제품의 신속한 출하와 검사실의 효율성 향상에 대한 요구 역시 증식 기반 검사법에 대한 수요를 지속적으로 뒷받침하고 있습니다.
“예측 기간 동안 아시아태평양이 신속 미생물 검사 시장에서 가장 높은 성장률을 나타낼 것으로 전망된다”
해당 지역에서는 의료 인프라 확충, 의료비 증가, 그리고 병원, 진단실험실, 의약품 제조 시설의 급속한 현대화에 힘입어 현저한 성장이 나타나고 있습니다. 감염병의 확산과 오염 관리 및 환자 안전에 대한 인식이 높아짐에 따라, 해당 지역 전체에서 신속 미생물 진단에 대한 수요가 증가하고 있습니다. 또한, 생명공학 연구, 바이오의약품 생산 및 실험실 자동화에 대한 투자 증가가 시장 확대를 더욱 촉진하고 있습니다. 분자진단, 신속 PCR 시스템 및 자동화된 미생물 동정 기술의 도입 확대 역시 시장 성장에 기여하고 있습니다. 지역 확장을 주도하는 주요 국가로는 중국, 인도, 일본, 한국이 포함됩니다.
신속 미생물 검사 시장의 주요 기업은 bioMerieux(프랑스), Waters Corporation(미국), Danaher Corporation(미국), Abbott Laboratories(미국), Thermo Fisher Scientific, Inc.(미국), Bruker Corporation(미국), QuidelOrtho Corporation(미국), Sartorius AG(독일), Merck KGaA(독일), F. Hoffmann-La Roche Ltd(스위스), Charles River Laboratories International, Inc.(미국), Neogen Corporation(미국), Bio-Rad Laboratories, Inc.(미국), Shimadzu Corporation(일본), Rapid Micro Biosystems, Inc.(미국)입니다.
조사 범위:
본 조사 보고서에서는 신속 미생물 검사 시장을 제품별(소모품, 기기, 시약 및 키트), 방법별(배양법, 세포 성분법, 핵산법, 생존율법, 기타), 용도별(산업용 검사, 임상 질환 진단, 연구 용도), 최종 사용자별(병원, 임상 실험실 및 ASC; 제약·바이오기술 기업, 식품 및 음료 기업, 환경·수질 검사 기관 및 기타 최종 사용자), 그리고 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)로 분류하고 있습니다.
본 보고서의 조사 범위에는 신속 미생물 검사 시장의 성장에 영향을 미치는 촉진요인, 제약 요인, 기회, 과제 등 주요 요인에 대한 상세한 정보가 포함되어 있습니다. 주요 업계 기업들에 대한 상세한 분석을 통해 각 기업의 사업 개요, 솔루션, 파트너십, 제휴, 사업 확장, 계약, 제품 출시, 신속 미생물 검사 시장의 최근 동향 등 주요 전략에 대한 인사이트를 제공합니다. 본 보고서에서는 신속 미생물 검사 생태계 내 신생 스타트업 기업들경쟁 구도에 대해서도 다루고 있습니다.
이 보고서를 구매해야 하는 이유:
본 보고서는 신속 미생물 검사 시장 전체 및 그 하위 부문의 매출에 대한 가장 정확한 추정치를 제공함으로써, 이 시장의 선도 기업과 신규 진출기업을 지원합니다. 본 보고서는 이해관계자들이 경쟁 구도를 이해하고, 더 깊은 인사이트를 얻어 자사의 비즈니스를 더 유리한 위치에 놓으며, 적절한 시장 진출 전략을 수립하는 데 도움이 됩니다. 또한, 본 보고서는 이해관계자들이 시장 동향을 파악하는 데 도움이 되며, 주요 시장 성장 촉진요인, 제약 요인, 기회 및 과제에 대한 정보를 제공합니다.
본 보고서에서는 다음 사항에 대한 인사이트를 제공합니다.
- 주요 촉진요인 분석(의료 관련 감염(HAI), 항생제 내성(AMR), 감염병 부담 증가; 자동화 미생물 검사 및 MALDI-TOF 플랫폼의 기술 발전; 식품 안전에 대한 우려 고조 및 식중독 발생률 증가; 미생물학 및 감염병 분야의 연구 개발(R&D) 활동 활성화), 제약 요인(막대한 설비 투자와 낮은 비용 대비 효과, 불리한 규제 및 보험 급여 환경, 숙련된 인력 부족), 기회(신흥 경제국에서의 신속 미생물 검사 수요 증가, 신속 미생물 검사의 적용 범위 확대), 과제(운영상의 장벽, 자동 미생물 동정 시스템에 대한 막대한 투자)
- 제품 개발 및 혁신 : 신속 미생물 검사 시장의 향후 기술, 연구 개발 활동 및 신제품 출시에 대한 상세한 분석.
- 시장 개발: 수익성이 높은 시장에 대한 종합적인 정보. 본 보고서에서는 다양한 지역의 신속 미생물 검사 시장을 분석했습니다.
- 시장의 다양화: 신속 미생물 검사 시장의 신제품, 미개척 지역, 최근 동향 및 투자에 관한 종합적인 정보.
- 경쟁사 분석 : bioMerieux(프랑스), Waters Corporation(미국), Danaher Corporation(미국), Abbott Laboratories(미국), Thermo Fisher Scientific, Inc.(미국) 등 주요 기업의 시장 점유율, 성장 전략, 제품 라인업에 대한 상세한 평가.
자주 묻는 질문
목차
제1장 서론
제2장 주요 요약
제3장 프리미엄 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI의 영향, 특허, 혁신, 그리고 향후 응용
제7장 규제 상황과 지속가능성 이니셔티브
제8장 고객 현황과 구매 행동
제9장 신속 미생물 검사 시장(제품별)
제10장 신속 미생물 검사 시장 : 수량 분석
제11장 신속 미생물 검사 시장(방법별)
제12장 신속 미생물 검사 시장(용도별)
제13장 신속 미생물 검사 시장(최종사용자별)
제14장 신속 미생물 검사 시장(지역별)
제15장 경쟁 구도
제16장 기업 개요
제17장 조사 방법
제18장 부록
LSHThe market for rapid microbiology testing is projected to grow from USD 5.69 billion in 2026 to USD 9.00 billion by 2031, reflecting a CAGR of 9.6%. Market growth is supported by rising pharmaceutical and biopharmaceutical production, stringent sterility and contamination control requirements, and expanding use of molecular diagnostics and automated microbiology systems.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product, Method, Application, End User, Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
Additionally, advancements in Polymerase Chain Reaction (PCR), mass spectrometry, and rapid microbial identification technologies are improving laboratory efficiency and supporting broader adoption globally.
"By product, reagents & Kits segment to showcase highest CAGR during forecast period"
The growth of the reagents & kits segment is primarily driven by the recurring demand for culture media, assay kits, primers, probes, stains, buffers, and antimicrobial susceptibility testing reagents used in rapid microbiology workflows. Rising incidences of infectious diseases and increasing emphasis on sterility assurance and contamination control are accelerating testing volumes across hospitals, pharmaceutical & biotechnology companies, and food testing laboratories. Additionally, expanding adoption of molecular microbiology techniques, automated testing platforms, and rapid PCR-based assays is expected to further drive demand for reagents & kits throughout the forecast period.
"By method, growth-based segment to hold the largest share of rapid microbiology testing market in 2026"
A growth-based rapid microbiology testing method is likely to dominate the market in 2026 due to its extensive use in pharmaceutical sterility testing, environmental monitoring, food safety testing, and clinical microbiology workflows. Growth-based rapid microbiology methods are widely adopted because they provide reliable detection of viable microorganisms while supporting regulatory compliance and quality assurance requirements. The increasing adoption of automated microbial detection systems, rising demand for faster contamination identification, and growing pharmaceutical and biopharmaceutical manufacturing activities are further driving segment growth. Additionally, the need for rapid product release and improved laboratory efficiency continues to support demand for growth-based testing methods.
"Asia Pacific to register fastest growth rate in rapid microbiology testing market during forecast period"
The region is witnessing significant growth due to expanding healthcare infrastructure, increasing healthcare expenditure, and rapid modernization of hospitals, diagnostic laboratories, and pharmaceutical manufacturing facilities. Rising prevalence of infectious diseases and growing awareness regarding contamination control and patient safety are increasing the demand for rapid microbial diagnostics across the region. Additionally, increasing investments in biotechnology research, biopharmaceutical production, and laboratory automation are further supporting market expansion. The growing adoption of molecular diagnostics, rapid PCR systems, and automated microbial identification technologies is also contributing to market growth. Major countries driving regional expansion include China, India, Japan, and South Korea.
Breakdown of primary participants in the rapid microbiology testing market is as follows:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
- By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
The key players in the rapid microbiology testing market are bioMerieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Bruker Corporation (US), QuidelOrtho Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories International, Inc. (US), Neogen Corporation (US), Bio-Rad Laboratories, Inc. (US), Shimadzu Corporation (Japan), and Rapid Micro Biosystems, Inc. (US).
Research Coverage:
This research report categorizes the rapid microbiology testing market by product (consumables, instruments, reagents & kits), method (growth-based, cellular component-based, nucleic acid-based, viability-based, and other methods) application (industrial testing, clinical disease diagnosis, and research applications), end user (hospitals, clinical laboratories, & ASCs; pharmaceutical & biotechnology companies; food & beverage companies; environmental & water testing laboratories; and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the rapid microbiology testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the rapid microbiology testing market. This report covers the competitive analysis of upcoming startups in the rapid microbiology testing ecosystem.
Reasons to Buy This Report:
The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall rapid microbiology testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases; technological advancements in automated microbiology and MALDI-TOF platforms; growing food safety concerns and rising incidence of foodborne illnesses; increasing R&D activities in microbiology and infectious disease), restraints (high capital investments and low cost-benefit ratio, unfavorable regulatory and reimbursement scenario, shortage of skilled personnel), opportunities (growing demand for rapid microbiology testing in emerging economies, expansion of rapid microbial testing applications), and challenges (operational barriers, high investment for automated microbial identification systems)
- Product development/innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the rapid microbiology testing market.
- Market development: Comprehensive information about lucrative markets; the report analyzes the rapid microbiology testing market across varied regions.
- Market diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the rapid microbiology testing market.
- Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like bioMerieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific, Inc. (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET
- 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 RAPID MICROBIOLOGY TESTING MARKET OVERVIEW
- 3.2 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT, 2026 VS. 2031
- 3.3 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD, 2026 VS. 2031
- 3.4 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION, 2026 VS. 2031
- 3.5 RAPID MICROBIOLOGY TESTING MARKET, BY END USER, 2026 VS. 2031
- 3.6 RAPID MICROBIOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases
- 4.2.1.2 Technological advancements in automated microbiology and MALDI-TOF platforms
- 4.2.1.3 Growing food safety concerns and rising incidence of foodborne illnesses
- 4.2.1.4 Increasing R&D in microbiology and infectious diseases
- 4.2.2 RESTRAINTS
- 4.2.2.1 High capital investments and low cost-benefit ratio
- 4.2.2.2 Unfavorable regulatory and reimbursement scenario
- 4.2.2.3 Shortage of skilled personnel
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Growing demand for rapid microbiology testing in emerging economies
- 4.2.3.2 Expansion of rapid microbial testing applications
- 4.2.4 CHALLENGES
- 4.2.4.1 Operational barriers
- 4.2.4.2 High investment for automated microbial identification systems
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.3.1 UNMET NEEDS IN RAPID MICROBIOLOGY TESTING MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 RAPID MICROBIOLOGY TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS
- 5.11.1 YOUNGS SEAFOOD ACCELERATED FOOD TESTING WITH VIDAS
- 5.11.2 RAPID MICROBIOLOGICAL METHOD CASE STUDY FOR ADVANCED THERAPY MEDICINAL PRODUCTS
- 5.11.3 RAPID DETECTION METHOD OF BACTERIAL PATHOGENS IN SURFACE WATERS AND NEW RISK INDICATOR FOR WATER PATHOGENIC POLLUTION
- 5.12 IMPACT OF US TARIFFS-RAPID MICROBIOLOGY TESTING MARKET
- 5.12.1 INTRODUCTION
- 5.12.2 KEY TARIFF RATES
- 5.12.3 PRICE IMPACT ANALYSIS
- 5.12.4 IMPACT ON COUNTRIES/REGIONS
- 5.12.4.1 North America
- 5.12.4.2 Europe
- 5.12.4.3 Asia Pacific
- 5.12.5 IMPACT ON END-USE INDUSTRIES
- 5.12.5.1 Hospitals, Clinical Laboratories, and ASCs
- 5.12.5.2 Pharmaceutical & Biotechnology Companies
- 5.12.5.3 Food & Beverage Companies
- 5.12.5.4 Environmental & Water Testing Laboratories
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 AUTOMATED MULTIPLEX PCR SYSTEMS
- 6.1.2 BIOSENSORS
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 OPTICAL IMMUNOSENSORS
- 6.2.2 ELECTROCHEMICAL IMMUNOSENSORS
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 DIGITAL PCR (DPCR)
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 LIST OF MAJOR PATENTS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GENERATIVE AI ON RAPID MICROBIOLOGY TESTING MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 TOP USE CASES AND MARKET POTENTIAL
- 6.7.3 KEY COMPANIES IMPLEMENTING AI
- 6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN RAPID MICROBIOLOGY TESTING
- 7.2.1.1 Eco-friendly Initiatives
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN RAPID MICROBIOLOGY TESTING
- 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT
- 9.1 INTRODUCTION
- 9.2 INSTRUMENTS
- 9.2.1 AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS
- 9.2.1.1 Ease of use compared to conventional identification processes to support market growth
- 9.2.2 MASS SPECTROMETERS
- 9.2.2.1 Rapid results associated with mass spectrometry methods to boost adoption
- 9.2.3 BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS
- 9.2.3.1 Unwanted detection of non-microbial ATP to limit market adoption
- 9.2.4 PCR SYSTEMS
- 9.2.4.1 Growing use of standard, real-time, and qPCR for rapid microbial testing to support growth
- 9.2.5 CYTOMETERS
- 9.2.5.1 Ability to detect viable organisms to favor market growth
- 9.2.6 ACTIVE AIR SAMPLERS
- 9.2.6.1 Convenience and ease of use to drive demand for active air samplers
- 9.2.7 OTHER INSTRUMENTS
- 9.2.1 AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS
- 9.3 REAGENTS & KITS
- 9.3.1 STERILITY TESTING REAGENTS & KITS
- 9.3.1.1 Increasing adoption of BET assays to propel market growth
- 9.3.2 OTHER REAGENTS & KITS
- 9.3.1 STERILITY TESTING REAGENTS & KITS
- 9.4 CONSUMABLES
- 9.4.1 DEVELOPMENT OF AUTOMATED ZONE READERS AND DISPENSERS TO DRIVE MARKET GROWTH
10 RAPID MICROBIOLOGY TESTING MARKET: VOLUME ANALYSIS
- 10.1 INTRODUCTION
- 10.2 GLOBAL: VOLUME OF MALDI-TOF MS MICROBIAL IDENTIFICATION SYSTEM INSTALLED BASE
11 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD
- 11.1 INTRODUCTION
- 11.2 GROWTH-BASED RAPID MICROBIOLOGY TESTING
- 11.2.1 RISING DEMAND FOR GROWTH-BASED TESTING TO DRIVE MARKET
- 11.3 CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING
- 11.3.1 HIGH SENSITIVITY, ACCURACY, AND SPECIFICITY OF CELLULAR COMPONENT-BASED METHODS TO BOOST MARKET
- 11.4 NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING
- 11.4.1 HIGH ACCURACY ASSOCIATED WITH NUCLEIC ACID-BASED METHODS TO FAVOR MARKET GROWTH
- 11.5 VIABILITY-BASED RAPID MICROBIOLOGY TESTING
- 11.5.1 NEAR REAL-TIME DETECTION AND IMPROVED ACCURACY TO DRIVE DEMAND
- 11.6 OTHER METHODS
12 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION
- 12.1 INTRODUCTION
- 12.2 INDUSTRIAL TESTING
- 12.2.1 FOOD & BEVERAGE TESTING
- 12.2.1.1 Stringent quality control and quality assurance processes to drive market growth
- 12.2.2 PHARMACEUTICAL & BIOLOGICAL DRUG TESTING
- 12.2.2.1 Improved regulatory scenario for drug development to support market growth
- 12.2.3 ENVIRONMENTAL TESTING
- 12.2.3.1 Growing focus on environmental monitoring to boost segmental growth
- 12.2.4 COSMETIC & PERSONAL CARE PRODUCTS TESTING
- 12.2.4.1 Growing use of rapid microbiology testing to determine the presence of microbes favors market growth
- 12.2.5 OTHER INDUSTRIAL TESTING APPLICATIONS
- 12.2.1 FOOD & BEVERAGE TESTING
- 12.3 CLINICAL DISEASE DIAGNOSIS
- 12.3.1 HIGH BURDEN OF INFECTIOUS DISEASES AND HEALTHCARE-ASSOCIATED INFECTIONS TO PROPEL MARKET GROWTH
- 12.4 RESEARCH
- 12.4.1 INCREASING NUMBER OF EPIDEMIOLOGY-BASED RESEARCH STUDIES TO DRIVE MARKET GROWTH
13 RAPID MICROBIOLOGY TESTING MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 HOSPITALS, CLINICAL LABORATORIES, AND ASCS
- 13.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
- 13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 13.3.1 STRINGENT GMP AND CONTAMINATION CONTROL REQUIREMENTS TO DRIVE TESTING DEMAND
- 13.4 FOOD & BEVERAGE COMPANIES
- 13.4.1 STRINGENT FOOD SAFETY REGULATIONS AND QUALITY CONTROL TO SUPPORT MARKET GROWTH
- 13.5 ENVIRONMENTAL & WATER TESTING LABORATORIES
- 13.5.1 GROWING FOCUS ON WATER SAFETY AND ENVIRONMENTAL MONITORING TO DRIVE DEMAND
- 13.6 OTHER END USERS
14 RAPID MICROBIOLOGY TESTING MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 14.2.2 US
- 14.2.2.1 Increasing prevalence of infectious diseases to drive market
- 14.2.3 CANADA
- 14.2.3.1 Supportive government initiatives and increased research funding to boost market
- 14.3 EUROPE
- 14.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 14.3.2 GERMANY
- 14.3.2.1 Favorable government policies to propel market
- 14.3.3 FRANCE
- 14.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market
- 14.3.4 UK
- 14.3.4.1 Emphasis on food contamination monitoring and hygiene controls to drive market
- 14.3.5 ITALY
- 14.3.5.1 Improved healthcare services and better disease surveillance to support market growth
- 14.3.6 SPAIN
- 14.3.6.1 Water monitoring mandate to boost market growth
- 14.3.7 RUSSIA
- 14.3.7.1 Strengthening water quality surveillance and outbreak response drives adoption in Russia
- 14.3.8 REST OF EUROPE
- 14.4 ASIA PACIFIC
- 14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 14.4.2 CHINA
- 14.4.2.1 Increasing government focus on disease prevention to drive market
- 14.4.3 JAPAN
- 14.4.3.1 Stringent safety laws and foodborne outbreaks to fuel uptake
- 14.4.4 INDIA
- 14.4.4.1 High target patient population to boost demand
- 14.4.5 SOUTH KOREA
- 14.4.5.1 Favorable government initiatives for medical tourism to support market growth
- 14.4.6 AUSTRALIA
- 14.4.6.1 Favorable healthcare automation techniques to support market growth
- 14.4.7 REST OF ASIA PACIFIC
- 14.5 LATIN AMERICA
- 14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 14.5.2 BRAZIL
- 14.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
- 14.5.3 MEXICO
- 14.5.3.1 Increasing prevalence of HIV to drive market
- 14.5.4 REST OF LATIN AMERICA
- 14.6 MIDDLE EAST & AFRICA
- 14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
- 14.6.2 SAUDI ARABIA
- 14.6.2.1 Increasing focus on healthcare automation to drive market
- 14.6.3 UNITED ARAB EMIRATES (UAE)
- 14.6.3.1 Improvements in healthcare infrastructure to support market growth
- 14.6.4 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
- 15.1 INTRODUCTION
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN RAPID MICROBIOLOGY TESTING MARKET
- 15.3 REVENUE ANALYSIS, 2023-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.5.5.1 Company footprint
- 15.5.5.2 Region footprint
- 15.5.5.3 Product footprint
- 15.5.5.4 Application footprint
- 15.5.5.5 End-user footprint
- 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.1 PROGRESSIVE COMPANIES
- 15.6.2 RESPONSIVE COMPANIES
- 15.6.3 DYNAMIC COMPANIES
- 15.6.4 STARTING BLOCKS
- 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 15.6.5.1 Detailed list of key startups/SMEs
- 15.6.5.2 Competitive benchmarking of startups/SMEs
- 15.7 COMPANY VALUATION & FINANCIAL METRICS
- 15.7.1 FINANCIAL METRICS
- 15.7.2 COMPANY VALUATION
- 15.8 BRAND/PRODUCT COMPARISON
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES & APPROVALS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 BIOMERIEUX
- 16.1.1.1 Business overview
- 16.1.1.2 Products offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product launches & approvals
- 16.1.1.3.2 Deals
- 16.1.1.3.3 Other developments
- 16.1.1.4 MnM view
- 16.1.1.4.1 Right to win
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses & competitive threats
- 16.1.2 WATERS CORPORATION
- 16.1.2.1 Business overview
- 16.1.2.2 Products offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product approvals
- 16.1.2.3.2 Deals
- 16.1.2.4 MnM view
- 16.1.2.4.1 Right to win
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses & competitive threats
- 16.1.3 DANAHER CORPORATION
- 16.1.3.1 Business overview
- 16.1.3.2 Products offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product approvals
- 16.1.3.3.2 Deals
- 16.1.3.4 MnM view
- 16.1.3.4.1 Right to win
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses & competitive threats
- 16.1.4 ABBOTT LABORATORIES
- 16.1.4.1 Business overview
- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Product approvals
- 16.1.4.4 MnM view
- 16.1.4.4.1 Right to win
- 16.1.4.4.2 Strategic choices
- 16.1.4.4.3 Weaknesses & competitive threats
- 16.1.5 THERMO FISHER SCIENTIFIC INC.
- 16.1.5.1 Business overview
- 16.1.5.2 Products offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product launches
- 16.1.5.3.2 Deals
- 16.1.5.4 MnM view
- 16.1.5.4.1 Right to win
- 16.1.5.4.2 Strategic choices
- 16.1.5.4.3 Weaknesses & competitive threats
- 16.1.6 BRUKER CORPORATION
- 16.1.6.1 Business overview
- 16.1.6.2 Products offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Product launches & approvals
- 16.1.6.3.2 Deals
- 16.1.7 QUIDELORTHO CORPORATION
- 16.1.7.1 Business overview
- 16.1.7.2 Products offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Product launches & approvals
- 16.1.7.3.2 Deals
- 16.1.7.3.3 Expansions
- 16.1.8 SARTORIUS AG
- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.9 MERCK KGAA
- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Product launches & approvals
- 16.1.10 F. HOFFMANN-LA ROCHE LTD
- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product launches & approvals
- 16.1.10.3.2 Deals
- 16.1.11 CHARLES RIVER LABORATORIES, INC.
- 16.1.11.1 Business overview
- 16.1.11.2 Products offered
- 16.1.11.3 Recent developments
- 16.1.11.3.1 Product launches
- 16.1.11.3.2 Deals
- 16.1.12 NEOGEN CORPORATION
- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Product launches
- 16.1.13 BIO-RAD LABORATORIES, INC.
- 16.1.13.1 Business overview
- 16.1.13.2 Products offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Product launches & approvals
- 16.1.13.3.2 Deals
- 16.1.14 SHIMADZU CORPORATION
- 16.1.14.1 Business overview
- 16.1.14.2 Products offered
- 16.1.14.3 Recent developments
- 16.1.14.3.1 Expansions
- 16.1.15 RAPID MICRO BIOSYSTEMS, INC.
- 16.1.15.1 Business overview
- 16.1.15.2 Products offered
- 16.1.15.3 Recent developments
- 16.1.15.3.1 Deals
- 16.1.1 BIOMERIEUX
- 16.2 OTHER PLAYERS
- 16.2.1 DON WHITLEY SCIENTIFIC LIMITED
- 16.2.2 GRADIENTECH
- 16.2.3 RQMICRO AG
- 16.2.4 COLIFAST AS
- 16.2.5 HYGIENA LLC
- 16.2.6 COPAN DIAGNOSTICS INC.
- 16.2.7 PERKINELMER INC.
- 16.2.8 HARDY DIAGNOSTICS
- 16.2.9 CHARM SCIENCES
- 16.2.10 R-BIOPHARM
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH DATA
- 17.2 RESEARCH APPROACH
- 17.2.1 SECONDARY RESEARCH
- 17.2.1.1 Key data from secondary sources
- 17.2.2 PRIMARY DATA
- 17.2.2.1 Primary sources
- 17.2.2.2 Key data from primary sources
- 17.2.2.3 Key industry insights
- 17.2.1 SECONDARY RESEARCH
- 17.3 MARKET SIZE ESTIMATION
- 17.3.1 BOTTOM-UP APPROACH
- 17.3.1.1 Approach 1: Company revenue estimation approach
- 17.3.1.2 Approach 2: Presentations of companies and primary interviews
- 17.3.1.3 Growth forecast
- 17.3.2 TOP-DOWN APPROACH
- 17.3.1 BOTTOM-UP APPROACH
- 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 17.5 MARKET SHARE ANALYSIS
- 17.6 RESEARCH ASSUMPTIONS
- 17.6.1 PARAMETRIC ASSUMPTIONS
- 17.6.2 GROWTH RATE ASSUMPTIONS
- 17.7 RESEARCH LIMITATIONS
- 17.8 RISK ASSESSMENT
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS
